Already clocked $39.10 which is 2 cents higher than previous. Not surprising that we pulled back from that resistance level, but stock is still strong today.
Early approval has another benefit, as it shows the high degree of confidence that the FDA had in approving the BLA, which should translate into physician confidence as well.
You can also adjust 2021 numbers upwards as the momentum of the 2020 sales will carry over to a quicker up ramp throughout the next year.
Have to also remember that T is not the only Ace in our hand, and that many more K research milestones are due shortly (which will also have a dramatic effect on earnings).
Congrats to all who didn't give up the fight (lost a few battles, but won the war). Nice to know that even those who bought at the previous highs are now made whole once again and looking forward to a profit.